NO20065012L - Tetrahydronaftyridin-derivater og fremgangsmate for fremstilling av disse - Google Patents
Tetrahydronaftyridin-derivater og fremgangsmate for fremstilling av disseInfo
- Publication number
- NO20065012L NO20065012L NO20065012A NO20065012A NO20065012L NO 20065012 L NO20065012 L NO 20065012L NO 20065012 A NO20065012 A NO 20065012A NO 20065012 A NO20065012 A NO 20065012A NO 20065012 L NO20065012 L NO 20065012L
- Authority
- NO
- Norway
- Prior art keywords
- processes
- preparation
- alkyl
- compound
- optionally substituted
- Prior art date
Links
- ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical class C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 title 1
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 abstract 2
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004109551 | 2004-04-02 | ||
| PCT/JP2005/006895 WO2005095395A2 (en) | 2004-04-02 | 2005-04-01 | Tetrahydronaphthyridine derivatives as cholesteryl ester transfer protein inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20065012L true NO20065012L (no) | 2006-12-28 |
Family
ID=35064445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20065012A NO20065012L (no) | 2004-04-02 | 2006-11-01 | Tetrahydronaftyridin-derivater og fremgangsmate for fremstilling av disse |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7781443B2 (ko) |
| EP (1) | EP1732924B1 (ko) |
| JP (1) | JP4633731B2 (ko) |
| KR (1) | KR100874623B1 (ko) |
| CN (1) | CN100441579C (ko) |
| AR (1) | AR048362A1 (ko) |
| AU (1) | AU2005228291B2 (ko) |
| BR (1) | BRPI0509588A (ko) |
| CA (1) | CA2560008C (ko) |
| IL (1) | IL178194A0 (ko) |
| MX (1) | MXPA06011416A (ko) |
| MY (1) | MY139887A (ko) |
| NO (1) | NO20065012L (ko) |
| NZ (1) | NZ550267A (ko) |
| RU (1) | RU2356902C2 (ko) |
| TW (1) | TWI345568B (ko) |
| WO (1) | WO2005095395A2 (ko) |
| ZA (1) | ZA200607782B (ko) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070208003A1 (en) * | 2004-03-26 | 2007-09-06 | Bell Michael G | Compounds and methods for treating dyslipidemia |
| WO2006069162A1 (en) | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds and their pharmaceutical compositions |
| CN101443006B (zh) | 2004-12-31 | 2012-10-10 | 雷迪美国治疗股份有限公司 | 作为cetp抑制剂的新颖的苄胺衍生物 |
| US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| JP4681526B2 (ja) * | 2005-09-29 | 2011-05-11 | 田辺三菱製薬株式会社 | 医薬組成物 |
| WO2007048027A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7790770B2 (en) | 2005-11-23 | 2010-09-07 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7652023B2 (en) | 2005-11-23 | 2010-01-26 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| PE20071025A1 (es) * | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
| US7750019B2 (en) | 2006-08-11 | 2010-07-06 | Kowa Company, Ltd. | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same |
| US7790737B2 (en) | 2007-03-13 | 2010-09-07 | Kowa Company, Ltd. | Substituted pyrimidine compounds and their utility as CETP inhibitors |
| US7659271B2 (en) | 2007-04-13 | 2010-02-09 | Kowa Company, Ltd. | Pyrimidine compound having dibenzylamine structure and medicament comprising the same |
| SI2207775T1 (sl) | 2007-11-05 | 2012-05-31 | Novartis Ag | benzilamino karboksiacil piperidinski derivati kot inhibitorji CETP uporabni za zdravljenje bolezni kot je hiperlipidemija ali arterioskleroza |
| CN101878199B (zh) * | 2007-12-03 | 2013-09-18 | 诺瓦提斯公司 | 用于治疗例如高血脂或动脉硬化疾病的作为cetp抑制剂的1，2-二取代的-4-苄基氨基-吡咯烷衍生物 |
| MX2011001887A (es) | 2008-08-22 | 2011-04-04 | Baxter Int | Derivados de bencil carbonato polimericos. |
| RU2012114770A (ru) * | 2009-09-04 | 2013-10-10 | Вандербилт Юниверсити | АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
| AU2010323227B2 (en) * | 2009-11-27 | 2015-11-19 | Adverio Pharma Gmbh | Method for producing methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate and its purification for use thereof as pharmaceutical substance |
| WO2012105574A1 (ja) * | 2011-01-31 | 2012-08-09 | 国立大学法人長崎大学 | 光学活性化合物又はその塩の製造方法 |
| JP5964965B2 (ja) | 2011-08-18 | 2016-08-03 | ドクター レディズ ラボラトリーズ リミテッド | コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物 |
| KR101803866B1 (ko) | 2011-09-27 | 2017-12-04 | 닥터 레디스 레보러터리즈 리미티드 | 동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체 |
| TWI570118B (zh) * | 2012-01-06 | 2017-02-11 | 第一三共股份有限公司 | 經取代之吡啶化合物的酸加成鹽 |
| US9067937B2 (en) | 2012-01-19 | 2015-06-30 | Oncotherapy Science, Inc. | 1,5-naphthyridine derivatives and MELK inhibitors containing the same |
| EP2919785A4 (en) | 2012-11-16 | 2016-10-05 | Biocryst Pharm Inc | ANTIVIRAL NUCLEOSIDES CONTAINING AZASUCRE |
| KR20190092539A (ko) | 2016-12-16 | 2019-08-07 | 바스프 에스이 | 살충 화합물 |
| EA039880B1 (ru) * | 2017-05-30 | 2022-03-23 | Дот Терапьютикс-1, Инк. | Способ получения оптически активного соединения |
| CN107245074B (zh) * | 2017-06-20 | 2019-04-09 | 牡丹江医学院附属红旗医院 | 用于治疗脑梗死的化合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| BR0307332A (pt) | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol |
| US20070208003A1 (en) * | 2004-03-26 | 2007-09-06 | Bell Michael G | Compounds and methods for treating dyslipidemia |
-
2005
- 2005-03-30 TW TW094109944A patent/TWI345568B/zh not_active IP Right Cessation
- 2005-03-30 MY MYPI20051440A patent/MY139887A/en unknown
- 2005-04-01 NZ NZ550267A patent/NZ550267A/en unknown
- 2005-04-01 CA CA2560008A patent/CA2560008C/en not_active Expired - Fee Related
- 2005-04-01 RU RU2006138597/04A patent/RU2356902C2/ru not_active IP Right Cessation
- 2005-04-01 WO PCT/JP2005/006895 patent/WO2005095395A2/en active Application Filing
- 2005-04-01 EP EP05728666A patent/EP1732924B1/en active Active
- 2005-04-01 AR ARP050101295A patent/AR048362A1/es not_active Application Discontinuation
- 2005-04-01 BR BRPI0509588-3A patent/BRPI0509588A/pt not_active IP Right Cessation
- 2005-04-01 KR KR1020067020091A patent/KR100874623B1/ko not_active IP Right Cessation
- 2005-04-01 AU AU2005228291A patent/AU2005228291B2/en not_active Ceased
- 2005-04-01 MX MXPA06011416A patent/MXPA06011416A/es active IP Right Grant
- 2005-04-01 JP JP2006534488A patent/JP4633731B2/ja not_active Expired - Fee Related
- 2005-04-01 CN CNB2005800104921A patent/CN100441579C/zh not_active Expired - Fee Related
-
2006
- 2006-09-18 ZA ZA200607782A patent/ZA200607782B/en unknown
- 2006-09-19 IL IL178194A patent/IL178194A0/en unknown
- 2006-09-27 US US11/527,556 patent/US7781443B2/en not_active Expired - Fee Related
- 2006-11-01 NO NO20065012A patent/NO20065012L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP4633731B2 (ja) | 2011-02-16 |
| AU2005228291B2 (en) | 2008-06-26 |
| KR100874623B1 (ko) | 2008-12-17 |
| CA2560008A1 (en) | 2005-10-13 |
| US7781443B2 (en) | 2010-08-24 |
| EP1732924B1 (en) | 2012-11-28 |
| EP1732924A2 (en) | 2006-12-20 |
| ZA200607782B (en) | 2008-02-27 |
| WO2005095395A3 (en) | 2006-06-01 |
| WO2005095395A2 (en) | 2005-10-13 |
| CN100441579C (zh) | 2008-12-10 |
| RU2356902C2 (ru) | 2009-05-27 |
| TW200536853A (en) | 2005-11-16 |
| MY139887A (en) | 2009-11-30 |
| KR20060132966A (ko) | 2006-12-22 |
| AU2005228291A1 (en) | 2005-10-13 |
| US20070032485A1 (en) | 2007-02-08 |
| NZ550267A (en) | 2009-08-28 |
| BRPI0509588A (pt) | 2007-09-25 |
| JP2007530444A (ja) | 2007-11-01 |
| CN1938301A (zh) | 2007-03-28 |
| CA2560008C (en) | 2010-06-01 |
| TWI345568B (en) | 2011-07-21 |
| RU2006138597A (ru) | 2008-05-10 |
| IL178194A0 (en) | 2006-12-31 |
| MXPA06011416A (es) | 2006-12-20 |
| AR048362A1 (es) | 2006-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20065012L (no) | Tetrahydronaftyridin-derivater og fremgangsmate for fremstilling av disse | |
| NO20065011L (no) | Tetrahydrokinolinderivater og fremgangsmate for fremstilling av disse | |
| JO2994B1 (ar) | مثبطات البروتين الناقل لاستر الكولسترول ( cetp ) | |
| TW200605883A (en) | Condensed heterocycle derivative having HCV inhibitory activity | |
| WO2008111604A1 (ja) | 新規なベンジル（ヘテロサイクリックメチル）アミン構造を有するピリミジン化合物及びこれを含有する医薬 | |
| DK1533292T3 (da) | Dibenzylaminforbindelse og medicinsk anvendelse deraf | |
| MX2009012283A (es) | Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1. | |
| NO331165B1 (no) | Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme for fremstilling av medikamenter | |
| NO20052469L (no) | Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2. | |
| NO20063446L (no) | Tiazolderivater | |
| NO20081464L (no) | 1-heterocyklusulfonyl, 2-aminometyl, 5-(hetero-)aryl subsidiert 1-H-pyrrol-derivater som syresekresjonsinhibitorer | |
| NO20074071L (no) | Hydrazinometyl, hydrozonometyl og 5-leddete heterocykliske forbindelser som virker som MTOR inhibitorer og anvendelse derav som anti-cancer midler | |
| NO20053133L (no) | Kjemiske forbindelser. | |
| NO20092770L (no) | Nye aminopyrimidinderivater som PLK1-inhibitorer | |
| WO2008108380A3 (en) | Pyrrole compounds | |
| NO20074763L (no) | (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi | |
| NO20055921L (no) | Heterocykliske metylsulfonderivater | |
| AU2003254852A8 (en) | Fused heterocyclic compounds as peptidase inhibitors | |
| EP1612204A4 (en) | HYDRAZONE DERIVATIVE | |
| MX2010010471A (es) | Derivado de tetrahidroisoquinolina novedoso. | |
| UA86077C2 (en) | Cetp inhibitors | |
| NO971687D0 (no) | Diazepinoindoler som forsfodiesterase IV-inhibitorer | |
| NO20065323L (no) | 6-substituerte pyridoindolonderivater, fremstilling og anvendelse derav | |
| ATE469156T1 (de) | 3,4 diaminopyridin-derivate | |
| NO20050572L (no) | Nye benzo[b]kromeno-naftyridin-7-on- og pyrano[2',3':7,8]kino[2,3-b]kinoksalin-7-on-forbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |